Hikma Pharmaceuticals stock names new CFO at EUR 0.85
Published on 09/29/2026 at 16:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Hikma Pharmaceuticals stock (ISIN GB00B128J450) was trading at EUR 0.85 at Lang & Schwarz on September 29, 2026 at 4:00 p.m. CEST, unchanged from the EUR 0.85 prior close. The company supplied a management catalyst on September 24, 2026, by appointing Rebecca Hall as its next chief financial officer.
New CFO joins in Q1 2027
According to Hikma, Hall will join in Q1 2027 and become an executive director. Current CFO Khalid Nabilsi is scheduled to step down from the Board on December 31, 2026, while continuing as deputy CEO for North America and Europe.
The change matters because Hall brings more than 20 years of experience from ViiV Healthcare and GSK, including senior finance, supply chain and business development responsibilities. The appointment adds a defined succession date to Hikma's operating plan while the group continues investing in its pipeline and manufacturing network.
Branded revenue grows 15.00 percent
Hikma's investor page says the company released interim results for the six months ended June 30, 2026, on August 6, 2026. In that H1 2026 update, Hikma reported Branded revenue growth of 15.00 percent year over year and reiterated its full-year 2026 guidance.
That segment comparison provides the clearest operating signal in the latest company update. Hikma runs three main businesses, Injectables, Branded and Hikma Rx, giving the group several revenue channels across North America, Europe and the Middle East and North Africa.
Targets reach GBp 2,100.00
Analyst expectations remain above the London quote. MarketBeat reported that Berenberg raised its target from GBp 1,800.00 to GBp 2,100.00 on August 11, 2026. The same report put the average one-year analyst target at GBp 2,085.83, with six research firms carrying Buy ratings.
The LSE quote stood at GBp 1,609.00 at 3:03 p.m. BST on September 29, 2026. Its 52-week range was GBp 1,187.00 to GBp 1,865.00, placing the latest London price below the yearly high while the euro quote remained flat against the previous Lang & Schwarz close.
EUR 0.85 quote stays flat
Hikma Pharmaceuticals was trading at EUR 0.85 at Lang & Schwarz on September 29, 2026 at 4:00 p.m. CEST, with a 0.00 percent change versus the EUR 0.85 prior close. The unchanged euro quote leaves the CFO transition, H1 operating progress and the analyst target gap as the main dated reference points for the stock.
Hikma Pharmaceuticals stock facts
- Company: Hikma Pharmaceuticals PLC
- ISIN: GB00B128J450
- Ticker: HIK
- Primary exchange: LSE
- Price Lang & Schwarz (as of September 29, 2026, 4:00 p.m. CEST): EUR 0.85
- Change versus prior close: 0.00 percent
- Prior close Lang & Schwarz (September 28, 2026): EUR 0.85
- 52-week range: GBp 1,187.00-GBp 1,865.00 (as of September 29, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - Specialty & Generic
